Pyxis Oncology, Inc. — Director's Dealing 2021

Oct 8, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXO)
CIK: 0001782223
Period of Report: 2021-10-07

Reporting Person: Bayer World Investments B.V. (10% Owner)
Reporting Person: BAYER AKTIENGESELLSCHAFT (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (1786831)		Direct
Series B Convertible Preferred Stock	$		Common Stock (955507)		Direct

Footnotes

F1: Shares of Series A and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") have no expiration date and, as of the date of this filing, are convertible, at the option of the Reporting Persons, into shares of the Issuer's common stock at a 6.359-for-1 conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares).

F2: Reflects that each 6.359 shares of Preferred Stock will convert automatically into one share of the Issuer's common stock at the closing of the Issuer's initial public offering, for no additional consideration (subject to the payment of cash in lieu of any fractional shares).

F3: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.